Furthermore, a precise cutoff for immunocytochemistry of TP53 in pituitary tumors has not yet been established, unlike the case in other endocrine tumors such as gastroenteropancreatic carcinomas.23 However, it is essential to recognize that no single marker is sufficient on its own to predict tumor behavior, and a combination of markers provides a more comprehensive assessment.9 This evidence concerns the gene TP53 and pituitary tumor.